Story
Self-Storage Spending Growth Slowed in August, Keybanc Data Shows

Summary
Consumer spending growth on self-storage decelerated sharply in August, according to Keybanc credit and debit card data, signaling potential headwinds for the sector as it enters its seasonally slower period.
Consumer spending growth in the self-storage sector decelerated significantly in August, according to an analysis of credit and debit card data by Keybanc. The slowdown suggests potential headwinds for operators as the industry moves into its seasonally slower fall leasing period.
August Data Shows Sharp Deceleration
Spending per transaction in the self-storage sector rose just 0.9% year-over-year in August, a marked slowdown from the 2.3% growth recorded in July, the Keybanc report stated. This represents a deceleration of 140 basis points from the previous month.
Key figures from the August data include:
- Average spending per transaction was $172.33, a 1.4% decrease from July’s $174.77.
- The month-over-month decline contrasts with a typical seasonal increase of 0.2%.
- Keybanc noted this was the second-weakest July-to-August change in its dataset, which spans over 10 years.
AdBroader Trends and Industry Outlook
The data, which Keybanc's report says serves as an indicator for in-place contract rents, showed moderating multi-month trends. On a three-month rolling basis from June through August, average revenue per transaction increased 1.3% year-over-year, down from 1.7% in the prior three-month period.
Keybanc noted that the August figures are consistent with recent commentary from self-storage real estate investment trusts (REITs) and private operators. The firm also suggested that a stable performance in September could support an acceleration in the third-quarter growth rate, as June's weaker 0.7% year-over-year comparison drops from the rolling calculation.
Read next
More on Stocks
Xenon Pharmaceuticals Stock Plummets Over 25% on Psychiatry Trial Enrollment Pause
Xenon Pharmaceuticals shares fell sharply after the company halted new patient enrollment in its late-stage psychiatry drug trials due to safety concerns, overshadowing a positive regulatory filing for its epilepsy treatment.

Steel Dynamics Shares Fall After Q3 Earnings Guidance Misses Estimates
The steel producer's stock declined in after-hours trading after it projected third-quarter earnings per share below the consensus forecast, disappointing investors despite a strong year-over-year outlook.

FDA Approves Ultragenyx's Fayuvi, First Gene Therapy for Sanfilippo Syndrome
The U.S. Food and Drug Administration has granted approval to Ultragenyx Pharmaceutical's gene therapy, Fayuvi, the first-ever treatment for a rare and fatal childhood neurological disease, causing the company's shares to surge.

Xenon Pharma Shares Fall After Pausing Enrollment in Psychiatry Trials
Xenon Pharmaceuticals announced a voluntary halt to new patient enrollment for its drug azetukalner in depression trials, citing safety concerns that sent its stock down as much as 16% in after-hours trading.